Recent regulatory filings indicate that Chidozie Ugwumba, acting through the entity SymBiosis II, LLC, has reduced his position in Clene Inc. (NASDAQ: CLNN) through a sequence of three distinct selling events. The transactions occurred between April 28 and April 30, 2026, with the total value of the common stock sold amounting to $112,778.
Breakdown of Transactions
The sales were executed at varying price points during the three-day period. On April 28, the first phase of selling involved the disposal of 1,591 shares at a price of $5.90 per share. This was followed on April 29 by a larger transaction consisting of 12,170 shares sold at a rate of $5.63 per share. The final transaction in this series took place on April 30, where 5,736 shares were sold at the highest price point of the period, $6.08 per share. Overall, the share prices for these transactions ranged from a low of $5.63 to a high of $6.08.
Following these specific divestments, Ugwumba maintains a substantial interest in the company, holding 277,569 shares of Clene Inc. common stock through SymBiosis II, LLC.
Market Context and Valuation
At the conclusion of these transactions, Clene Inc. stock closed at $6.16. Looking at historical performance, the equity has seen significant volatility; it has achieved a 107% return over the past year, yet it has experienced a decline of 51% over the preceding six-month period. While Fair Value analysis suggests that the stock may currently be undervalued, Clene Inc.'s broader financial standing is characterized as "WEAK."
Key Market Insights
- Insider Divestment: A 10% owner has liquidated a portion of their holdings, totaling $112,778 in common stock.
- Price Volatility: The company's stock shows a wide divergence between its annual gains (up 107%) and its six-month performance (down 51%).
- Valuation Discrepancy: There is a notable contrast between the perceived undervaluation of the stock and the "WEAK" rating assigned to the company's financial health.
Risks and Uncertainties
- Financial Stability Risks: The company's overall financial health is currently rated as "WEAK," which may impact stability within the broader biotech or micro-cap sectors.
- Stock Volatility: Significant fluctuations in share price, such as the 51% decline over six months, present risks for market participants and investors tracking equity momentum.